PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32645631-8	2020	Baricitinib decreased the systemic inflammation by lowering expression of IL-6 and CRP and reducing ESR and serum concentrations of adiponectin.	baricitinib	0-11	C-reactive protein	Homo sapiens	83-86	
34136969-6	2021	Compared to treatment with tocilizumab, baricitinib showed a similar improvement in tender and swollen joint count and serum CRP levels, and a significantly greater improvement in PGA at 24 weeks.	baricitinib	40-51	C-reactive protein	Homo sapiens	125-128	
29680881-8	2018	At weeks 12 and 24, baricitinib-treated patients had larger responses compared to placebo-treated patients for multiple efficacy outcomes: American College of Rheumatology 20/50/70 response, low disease activity, remission, Disease Activity Score 28-C-reactive protein, and Health Assessment Questionnaire-Disability Index.	baricitinib	20-31	C-reactive protein	Homo sapiens	250-268